Author: COUR Pharma

Posted Date:

March 3, 2026

COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis

COUR Pharma

March 3, 2026
COUR Pharma Publishes Peer-Reviewed Data in Science Advances

COUR Pharma

January 28, 2026